Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized trial

Paulien G Westhoff, Alexander de Graeff, Jenske I Geerling, Anna K L Reyners, Yvette M van der Linden, Paulien G Westhoff, Alexander de Graeff, Jenske I Geerling, Anna K L Reyners, Yvette M van der Linden

Abstract

Background: Radiotherapy has a good effect in palliation of painful bone metastases, with a pain response rate of more than 60%. However, shortly after treatment, in approximately 40% of patients a temporary pain flare occurs, which is defined as a two-point increase of the worst pain score on an 11-point rating scale compared to baseline, without a decrease in analgesic intake, or a 25% increase in analgesic intake without a decrease in worst pain score, compared to baseline. A pain flare has a negative impact on daily functioning and mood of patients. It is thought to be caused by periostial edema after radiotherapy. Dexamethasone might diminish this edema and thereby reduce the incidence of pain flare. Two non-randomized studies suggest that dexamethasone reduces the incidence of a pain flare by 50%. The aim of this trial is to study the effectiveness of dexamethasone to prevent a pain flare after palliative radiotherapy for painful bone metastases and to determine the optimal dose schedule.

Methods and design: This study is a three-armed, double-blind, placebo-controlled multicenter trial. We aim to include 411 patients with uncomplicated painful bone metastases from any type of primary solid tumor who receive short schedule radiotherapy (all conventional treatment schedules from one to six fractions). Arm 1 consists of daily placebo for four days, arm 2 starts with 8 mg dexamethasone before the (first) radiotherapy and three days placebo thereafter. Arm 3 consists of four days 8 mg dexamethasone. The primary endpoint is the occurrence of a pain flare. Secondary endpoints are pain, quality of life and side-effects of dexamethasone versus placebo. Patients complete a questionnaire (Brief Pain Inventory with two added questions about side-effects of medication, the EORTC QLQ-C15-PAL and QLQ-BM22 for quality of life) at baseline, daily for two weeks and lastly at four weeks.

Discussion: This study will show whether dexamethasone is effective in preventing a pain flare after palliative radiotherapy for painful bone metastases and, if so, to determine the optimal dose.

Trial registration: This study is registered at ClinicalTrials.gov: NCT01669499.

Figures

Figure 1
Figure 1
Treatment arms.

References

    1. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–1436. doi: 10.1200/JCO.2006.09.5281.
    1. Chow E, Ling A, Davis L, Panzarella T, Danjoux C. Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol. 2005;75(1):64–69. doi: 10.1016/j.radonc.2004.12.016.
    1. Hird A, Chow E, Zhang L, Wong R, Wu J, Sinclair E, Danjoux C, Tsao M, Barnes E, Loblaw A. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys. 2009;75(1):193–197. doi: 10.1016/j.ijrobp.2008.10.044.
    1. Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, Warde P. Pain flare in patients with bone metastases after palliative radiotherapy–a nested randomized control trial. Support Care Cancer. 2007;15(4):451–455. doi: 10.1007/s00520-006-0166-y.
    1. Hird A, Wong R, Flynn C, Hadi S, de Sa E, Zhang L, DeAngelis C, Chow E. Impact of pain flare on patients treated with palliative radiotherapy for symptomatic bone metastases. J Pain Manag. 2009;2(4):401–406.
    1. Hird A, Zhang L, Holt T, Fairchild A, DeAngelis C, Loblaw A, Wong R, Barnes E, Tsao M, Danjoux C, Chow E. Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases: a phase II study. Clin Oncol (R Coll Radiol) 2009;21(4):329–335. doi: 10.1016/j.clon.2008.12.010.
    1. Chow E, Loblaw A, Harris K, Doyle M, Goh P, Chiu H, Panzarella T, Tsao M, Barnes EA, Sinclair E, Farhadian M, Danjoux C. Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a pilot study. Support Care Cancer. 2007;15(6):643–647. doi: 10.1007/s00520-007-0217-z.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB. EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42(1):55–64. doi: 10.1016/j.ejca.2005.06.022.
    1. Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, Wu J, Shafiq J, Sezer O, Kardamakis D, Linden Y, Ma B, Castro M, Arnalot PF, Ahmedzai S, Clemons M, Hoskin P, Yee A, Brundage M, Bottomley A. EORTC Quality of Life Group, Collaboration for Cancer Outcomes Research and Evaluation. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer. 2009;45(7):1146–1152. doi: 10.1016/j.ejca.2008.11.013.
    1. Chiang A, Zeng L, Zhang L, Lochray F, Korol R, Loblaw A, Chow E, Sahgal A. Pain flare is a common adverse event in steroid-naive patients after spine stereotactic body radiation therapy: a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013;86(4):638–642. doi: 10.1016/j.ijrobp.2013.03.022.
    1. Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E. on behalf of the International Bone Metastases Consensus Working Party. Update of the International Consensus on Palliative Radiotherapy Endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):1730–1737. doi: 10.1016/j.ijrobp.2011.02.008.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner